1. Clinical Considerations in the Management of EGFR-Mutated Advanced NSCLC

4. EGFR Inhibitors for NSCLC A Paradigm Shift in Treatment

5. Overview of Nurses' Role in Managing Patients With Lung Cancer

6. Case 68-Year-Old Woman

7. Symptoms in a Patient With Newly Diagnosed NSCLC

8. Molecular Profiling of NSCLC

9. Case (cont)

10. Therapies for EGFR-Positive NSCLC

11. Initial Conversations With the Patient

12. Notable Adverse Effects of EGFR TKIs

13. Skin Rash

14. Prevalence of Rash With EGFR Inhibitors

15. Rash and EGFR Inhibitors Improved Outcomes in NSCLC

16. Strategies to Prevent Dermatologic Toxicities

17. STEPP Study Preemptive vs Reactive Management of Skin Toxicities

18. MASCC Recommendations for Prevention of Rash

19. Case (cont)

20. MASCC Recommendations for Treatment of Rash

21. Other Adverse Effects of EGFR TKIs

22. Paronychia

23. Scalp Rash

24. Dose Reductions

25. Management of Other Adverse Effects

26. Precautions With Concurrent Medications

27. Case (cont)

28. Development of Acquired Resistance to EGFR TKIs

29. Osimertinib: Efficacy and Safety

30. Case (cont)

31. Take-Home Messages

32. Abbreviations

33. Abbreviations (cont)